Drug Trial Radar · NCT07676006
A Clinical Study to Investigate the Safety and Efficacy of Off-the-Shelf iNKT Cell Injection Targeting CD33/CD70 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
Last checked: Nov 20, 2026Latest source record: Sep 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
36
Planned (sponsor's estimate)
Start
May 2027
Primary completion
Jun 2030
Study completion Jun 2030
Sponsor
- Lead sponsor
- Grit BiotechnologyIndustry
- Sponsor type
- Industry
- Collaborators
- Shenzhen People's Hospital
- First posted
- Jun 30, 2026
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a single-arm, open-label, dose-escalation, prospective exploratory clinical study intended to evaluate the safety, efficacy and cellular pharmacokinetics of GT737 cells in adult patients with relapsed/refractory acute myeloid leukemia (AML).
Conditions
- Relapsed/Refractory Acute Myeloid Leukemia (AML)
Interventions
GT737 InjectionBiological
GT737 Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants experiencing dose limiting toxicityTime frame: 28 days
- Adverse Events (AEs) occurring after infusion and their proportionsTime frame: 28 days
- Severity of Adverse Events (AEs) after infusionTime frame: 28 days
- Compare the differences in safety and tolerability between different treatment subgroups (monotherapy and combination with sirolimus).Time frame: 28 Days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Shenzhen People's Hospital
Shenzhen, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.